These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34985974)

  • 1. Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2.
    Sun X; Yang S; Al-Dossary AA; Broitman S; Ni Y; Guan M; Yang M; Li J
    Appl Environ Microbiol; 2022 Mar; 88(5):e0230321. PubMed ID: 34985974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
    Huang SW; Miller SO; Yen CH; Wang SF
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
    Cheng YW; Chao TL; Li CL; Wang SH; Kao HC; Tsai YM; Wang HY; Hsieh CL; Lin YY; Chen PJ; Chang SY; Yeh SH
    mBio; 2021 Aug; 12(4):e0058721. PubMed ID: 34311586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertical Flow Cellulose-Based Assays for SARS-CoV-2 Antibody Detection in Human Serum.
    Kim S; Hao Y; Miller EA; Tay DMY; Yee E; Kongsuphol P; Jia H; McBee M; Preiser PR; Sikes HD
    ACS Sens; 2021 May; 6(5):1891-1898. PubMed ID: 33822583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalized TiO
    Vadlamani BS; Uppal T; Verma SC; Misra M
    Sensors (Basel); 2020 Oct; 20(20):. PubMed ID: 33080785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
    Gellenoncourt S; Saunders N; Robinot R; Auguste L; Rajah MM; Kervevan J; Jeger-Madiot R; Staropoli I; Planchais C; Mouquet H; Buchrieser J; Schwartz O; Chakrabarti LA
    J Virol; 2022 Oct; 96(19):e0130122. PubMed ID: 36121299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.
    Liu J; Chen X; Liu Y; Lin J; Shen J; Zhang H; Yin J; Pu R; Ding Y; Cao G
    Infect Dis Poverty; 2021 Aug; 10(1):112. PubMed ID: 34419160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
    Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable nanocatchers for SARS-CoV-2 inhibition.
    Zhang H; Zhu W; Jin Q; Pan F; Zhu J; Liu Y; Chen L; Shen J; Yang Y; Chen Q; Liu Z
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34292870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.